Developer docs
API playgroundTry for free, no card

Search company profiles

Janux Therapeutics

Full company profile

uuid0000bgo

Namestring
Janux Therapeutics
Legal namestring
Janux Therapeutics, Inc.
Websiteurl
januxrx.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Janux Therapeutics is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in La Jolla/San Diego, California, that develops bispecific T cell engagers designed to be activated selectively within tumor tissue. The company's product engine rests on three proprietary platforms: TRACTr (tumor-activated T cell engagers with cleavable peptide masking), TRACIr (tumor-activated immunomodulators), and ARM (albumin-binding masked T cell recruiters), all engineered to circulate inertly until tumor-associated proteases unmask the binding domain, with albumin binding used to extend serum half-life and support flat rather than continuous dosing.

The current clinical-stage pipeline is concentrated in prostate cancer and autoimmune disease. Lead oncology assets include JANX007 and JANX014, both PSMA-directed TRACTr molecules in Phase 1 for metastatic castration-resistant prostate cancer, with JANX007 interim data reported in late 2025 showing median rPFS of roughly 7.9-8.9 months. JANX011 is a CD19-directed ARM candidate being advanced into autoimmune indications, while JANX013 (PSMA-TRACIr) and JANX008 (a TRACIr prostate candidate discontinued in April 2026) illustrate the iterative scope of the program.

Janux operates as a licensing- and collaboration-driven development company. Revenue is generated almost entirely from upfront and milestone payments tied to pharmaceutical partnerships: an initial collaboration with Merck covering multiple TRACTr programs (signed December 2020, valued at over $1B in potential milestones), and a January 2026 Bristol Myers Squibb collaboration worth up to $850M with $50M paid upfront, followed by an April 2026 $35M development milestone. Janux is publicly traded on NASDAQ under the ticker JANX following its June 2021 IPO and, with Q4 2025 revenue of $7.88M and a net loss of $113.6M for full-year 2025 against approximately $966.6M of cash at year-end, is funded principally through equity and partnership economics rather than product sales.

Short descriptiontext

Janux Therapeutics is a clinical-stage biopharmaceutical company that develops tumor-activated bispecific T cell engagers using proprietary TRACTr, TRACIr and ARM platforms to treat prostate cancer and autoimmune diseases, monetized through licensing and milestone payments from Merck and Bristol Myers Squibb.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific immunotherapy, tumor-activated therapeutics, T cell engagers, clinical-stage biopharmaceuticals, bispecific antibody drug development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage immuno-oncology biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Strategic Partnerships and Licensing (Merck)
TypeLicensing Royalties
Description

In December 2020, Janux entered a research collaboration and exclusive license agreement with Merck to develop TRACTr product candidates. Merck exercised its right to select both collaboration targets. Janux receives upfront, milestone, and potential royalty payments. Merck leads clinical development and commercialization. In August 2025, the first patient was dosed in the lead collaboration program.

fiercebiotech.com
2Strategic Partnerships and Licensing (Bristol Myers Squibb)
TypeLicensing Royalties
Description

In January 2026, Janux entered a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb for a novel tumor-activated therapeutic targeting a validated solid tumor antigen. Janux receives $50 million in upfront and near-term payments plus up to approximately $800 million in development, regulatory, and commercial milestones, plus tiered royalties on global sales. Janux conducts preclinical development through IND submission, then BMS leads clinical development and global commercialization.

businesswire.com
3Milestone Payments from Partnerships
TypeLicensing Royalties
Description

Janux generates non-dilutive capital through milestone payments triggered by development, regulatory, and commercial achievements under its partnership agreements. The company received a $35 million milestone payment from Bristol Myers Squibb in April 2026 following nomination of a development candidate.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Janux Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies using three proprietary platforms (TRACTr, TRACIr, and ARM) that employ peptide masking technology to keep T cell-binding domains inactive until cleaved by tumor-specific proteases in the tumor microenvironment. Its pipeline includes PSMA-directed T cell engagers for metastatic castration-resistant prostate cancer (JANX007, JANX014), a CD19-targeted candidate for autoimmune disease (JANX011), and a PSMA-directed T cell costimulator (JANX013), with commercialization rights primarily licensed to Merck and Bristol Myers Squibb.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Median radiographic progression-free survival of 7.9 to 8.9 months in mCRPC patients treated with JANX007 (Phase 1 data, December 2025)
+3 more records
Product overview1 text field

Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies using three proprietary technology platforms: TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator). The TRACTr and TRACIr platforms are designed to selectively activate T cells in the tumor microenvironment while minimizing systemic toxicity, using tumor-specific protease-cleavable peptide masks. The ARM platform enables redesigned bispecific T-cell engagers for autoimmune disease applications. The company's pipeline includes wholly-owned programs (JANX007, JANX014, JANX011, JANX013) targeting PSMA for prostate cancer and CD19 for autoimmune diseases, as well as partnered programs with Merck and Bristol Myers Squibb.

Product and service7 records
1JANX007 (PSMA-TRACTr)
CategoryDrug Candidate
Description

Lead Tumor Activated T Cell Engager (TRACTr) targeting PSMA (prostate-specific membrane antigen) for treatment of metastatic castration-resistant prostate cancer (mCRPC). Single-masked TRACTr where the PSMA-binding domain is unmasked and CD3 is masked to minimize cytokine release syndrome.

2JANX014 (PSMA-TRACTr)
CategoryDrug Candidate
Description

Novel double-masked Tumor Activated T Cell Engager (TRACTr) targeting PSMA for metastatic castration-resistant prostate cancer. Both PSMA-binding and CD3 domains are masked to enable tumor-selective T cell activation and refined safety including minimization of cytokine release syndrome risk.

3JANX011 (CD19-ARM)
CategoryDrug Candidate
Description

CD19-targeted Adaptive Immune Response Modulator designed for autoimmune diseases. JANX011 drives prolonged drug-free remissions as an off-the-shelf re-dosable therapeutic, demonstrating deep and durable B-cell depletion with prolonged memory B-cell reset and no evidence of cytokine release syndrome in preclinical studies.

4JANX013 (PSMA-TRACIr)
CategoryDrug Candidate
Description

Novel tumor-activated immune modulator targeting PSMA engineered to deliver CD28-mediated co-stimulation selectively within the tumor microenvironment. Designed to be developed in combination with JANX007 in patients with metastatic castration-resistant prostate cancer.

5TRACTr Platform
CategoryTechnology Platform
Description

Tumor Activated T Cell Engager platform that uses proprietary masking technology to engineer novel drug candidates designed to overcome traditional TCE toxicity and efficacy limitations. TRACTrs comprise a tumor antigen-binding domain and a T cell binding domain (CD3), with the CD3 binding domain protected by a domain-optimized peptide mask cleaved at the tumor via tumor-specific proteases.

6TRACIr Platform
CategoryTechnology Platform
Description

Tumor Activated Immunomodulator platform that utilizes a tumor antigen-binding domain linked to a T cell costimulatory CD28 binding domain. The CD28 binding domain is masked and selectively activated in the tumor microenvironment to deliver CD28-mediated co-stimulation within the tumor.

7ARM Platform
CategoryTechnology Platform
Description

Adaptive Immune Response Modulator platform for developing redesigned bispecific T-cell engagers to improve efficacy and durability of response with a large safety window, intended for autoimmune disease applications. First clinical candidate JANX011 targets CD19 for deep and durable B-cell depletion in autoimmune diseases.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Bristol Myers Squibb (BMS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

In January 2026, Janux entered a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across multiple cancer types. Janux receives $50M in upfront and near-term payments plus up to approximately $800M in additional milestones, plus tiered royalties on global sales. Janux conducts preclinical development through IND submission; BMS leads subsequent clinical development and global commercialization, with Janux remaining actively involved through completion of the first Phase 1 clinical study. A $35M milestone was triggered in April 2026 following nomination of a development candidate.

januxrx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-01
Description

In December 2020, Janux entered a research collaboration and exclusive license agreement with Merck to develop TRACTr two product candidates distinct from Janux's internally developed pipeline. Merck exercised its right to select both collaboration targets related to next-generation TCE immunotherapies for cancer treatment. In August 2025, Janux announced the first patient was dosed in the lead collaboration program. Deal value exceeds $1 billion in total potential payments.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech with bispecific antibody candidates (e.g., CD3-engaging formats) for oncology. Small capitalization peer with a comparable technology platform and indication focus.

TypeDirect peer
Description

Develops DART and TRIDENT bispecific antibody platforms, including T cell engagers and ADCs targeting oncology antigens; partnered with multiple Big Pharma. Closely comparable format and indication overlap (solid tumors, hematologic cancers).

TypeDirect peer
Description

Clinical-stage biotech with the XmAb bispecific antibody platform used by multiple partners to build T cell engagers (e.g., CD3-engaging formats) for oncology and autoimmune. Operates a similar platform-plus-partnership business model.

TypeDirect peer
Description

Develops Azymetric bispecific antibodies and other multispecific platforms for oncology and autoimmune indications, including T cell engaging constructs; similar pipeline breadth and partnership-driven commercialization model.

TypeBroad incumbent
Description

Pioneered the BiTE platform (blinatumomab is approved) and continues to develop CD3-bispecifics across solid and hematologic tumors; sets the competitive baseline for any new TCE entrant in oncology.

TypeDirect peer
Description

Pre-IPO developer of conditional T cell engagers (COBRA platform) targeting solid tumors, including a PSMA-directed candidate; acquired by Takeda in 2022. Closest technology competitor in masking-based TCEs.

TypeDirect peer
Description

Developed T cell engagers with a proprietary masking/half-life-extension platform (TriTAC) targeting solid tumor antigens including PSMA; acquired by Merck in 2024. Closest technology analog to Janux's TRACTr platform and now a program counterpart inside Janux's Merck partner.

TypeDirect peer
Description

Owns the DuoBody bispecific platform used in oncology therapeutics including T cell engagers and antibody-drug conjugates; partnered broadly with Big Pharma. Direct structural analog to Janux's bispecific platform strategy.

TypeBroad incumbent
Description

Develops CD3-engaging bispecific antibodies (e.g., CD20×CD3 linvoseltamab, earlier REGN1979) as part of a large oncology and immunology portfolio. Operates bispecific programs at greater scale and commercial reach than Janux.

TypeEmerging player
Description

Clinical-stage developer of precision oncology biologics including T cell engaging modalities; smaller-cap competitor with overlapping bispecific/TCE approaches for solid tumors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Janux Therapeutics

Clinical-stage immuno-oncology biopharmaceuticalsjanuxrx.com

Janux Therapeutics is a clinical-stage biopharmaceutical company that develops tumor-activated bispecific T cell engagers using proprietary TRACTr, TRACIr and ARM platforms to treat prostate cancer and autoimmune diseases, monetized through licensing and milestone payments from Merck and Bristol Myers Squibb.

What Janux Therapeutics does

Janux Therapeutics is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in La Jolla/San Diego, California, that develops bispecific T cell engagers designed to be activated selectively within tumor tissue. The company's product engine rests on three proprietary platforms: TRACTr (tumor-activated T cell engagers with cleavable peptide masking), TRACIr (tumor-activated immunomodulators), and ARM (albumin-binding masked T cell recruiters), all engineered to circulate inertly until tumor-associated proteases unmask the binding domain, with albumin binding used to extend serum half-life and support flat rather than continuous dosing.

The current clinical-stage pipeline is concentrated in prostate cancer and autoimmune disease. Lead oncology assets include JANX007 and JANX014, both PSMA-directed TRACTr molecules in Phase 1 for metastatic castration-resistant prostate cancer, with JANX007 interim data reported in late 2025 showing median rPFS of roughly 7.9-8.9 months. JANX011 is a CD19-directed ARM candidate being advanced into autoimmune indications, while JANX013 (PSMA-TRACIr) and JANX008 (a TRACIr prostate candidate discontinued in April 2026) illustrate the iterative scope of the program.

Janux operates as a licensing- and collaboration-driven development company. Revenue is generated almost entirely from upfront and milestone payments tied to pharmaceutical partnerships: an initial collaboration with Merck covering multiple TRACTr programs (signed December 2020, valued at over $1B in potential milestones), and a January 2026 Bristol Myers Squibb collaboration worth up to $850M with $50M paid upfront, followed by an April 2026 $35M development milestone. Janux is publicly traded on NASDAQ under the ticker JANX following its June 2021 IPO and, with Q4 2025 revenue of $7.88M and a net loss of $113.6M for full-year 2025 against approximately $966.6M of cash at year-end, is funded principally through equity and partnership economics rather than product sales.

Janux Therapeutics firmographics

Firmographics
Name
Janux Therapeutics
Legal name
Janux Therapeutics, Inc.
Website
https://januxrx.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Janux Therapeutics is a clinical-stage biopharmaceutical company that develops tumor-activated bispecific T cell engagers using proprietary TRACTr, TRACIr and ARM platforms to treat prostate cancer and autoimmune diseases, monetized through licensing and milestone payments from Merck and Bristol Myers Squibb.
Ownership category
akta.pro rank

Where Janux Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Janux Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Strategic Partnerships and Licensing (Merck): In December 2020, Janux entered a research collaboration and exclusive license agreement with Merck to develop TRACTr product candidates. Merck exercised its right to select both collaboration targets. Janux receives upfront, milestone, and potential royalty payments. Merck leads clinical development and commercialization. In August 2025, the first patient was dosed in the lead collaboration program.
  2. Strategic Partnerships and Licensing (Bristol Myers Squibb): In January 2026, Janux entered a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb for a novel tumor-activated therapeutic targeting a validated solid tumor antigen. Janux receives $50 million in upfront and near-term payments plus up to approximately $800 million in development, regulatory, and commercial milestones, plus tiered royalties on global sales. Janux conducts preclinical development through IND submission, then BMS leads clinical development and global commercialization.
  3. Milestone Payments from Partnerships: Janux generates non-dilutive capital through milestone payments triggered by development, regulatory, and commercial achievements under its partnership agreements. The company received a $35 million milestone payment from Bristol Myers Squibb in April 2026 following nomination of a development candidate.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Janux Therapeutics product offering

Product offering

Core offering

Janux Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies using three proprietary platforms (TRACTr, TRACIr, and ARM) that employ peptide masking technology to keep T cell-binding domains inactive until cleaved by tumor-specific proteases in the tumor microenvironment. Its pipeline includes PSMA-directed T cell engagers for metastatic castration-resistant prostate cancer (JANX007, JANX014), a CD19-targeted candidate for autoimmune disease (JANX011), and a PSMA-directed T cell costimulator (JANX013), with commercialization rights primarily licensed to Merck and Bristol Myers Squibb.

Product overview

Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies using three proprietary technology platforms: TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator). The TRACTr and TRACIr platforms are designed to selectively activate T cells in the tumor microenvironment while minimizing systemic toxicity, using tumor-specific protease-cleavable peptide masks. The ARM platform enables redesigned bispecific T-cell engagers for autoimmune disease applications. The company's pipeline includes wholly-owned programs (JANX007, JANX014, JANX011, JANX013) targeting PSMA for prostate cancer and CD19 for autoimmune diseases, as well as partnered programs with Merck and Bristol Myers Squibb.

Differentiator

Problem solved

Functional benefit

Products and services

  • JANX007 (PSMA-TRACTr) Lead Tumor Activated T Cell Engager (TRACTr) targeting PSMA (prostate-specific membrane antigen) for treatment of metastatic castration-resistant prostate cancer (mCRPC). Single-masked TRACTr where the PSMA-binding domain is unmasked and CD3 is masked to minimize cytokine release syndrome.
  • JANX014 (PSMA-TRACTr) Novel double-masked Tumor Activated T Cell Engager (TRACTr) targeting PSMA for metastatic castration-resistant prostate cancer. Both PSMA-binding and CD3 domains are masked to enable tumor-selective T cell activation and refined safety including minimization of cytokine release syndrome risk.
  • JANX011 (CD19-ARM) CD19-targeted Adaptive Immune Response Modulator designed for autoimmune diseases. JANX011 drives prolonged drug-free remissions as an off-the-shelf re-dosable therapeutic, demonstrating deep and durable B-cell depletion with prolonged memory B-cell reset and no evidence of cytokine release syndrome in preclinical studies.
  • JANX013 (PSMA-TRACIr) Novel tumor-activated immune modulator targeting PSMA engineered to deliver CD28-mediated co-stimulation selectively within the tumor microenvironment. Designed to be developed in combination with JANX007 in patients with metastatic castration-resistant prostate cancer.
  • TRACTr Platform Tumor Activated T Cell Engager platform that uses proprietary masking technology to engineer novel drug candidates designed to overcome traditional TCE toxicity and efficacy limitations. TRACTrs comprise a tumor antigen-binding domain and a T cell binding domain (CD3), with the CD3 binding domain protected by a domain-optimized peptide mask cleaved at the tumor via tumor-specific proteases.
  • TRACIr Platform Tumor Activated Immunomodulator platform that utilizes a tumor antigen-binding domain linked to a T cell costimulatory CD28 binding domain. The CD28 binding domain is masked and selectively activated in the tumor microenvironment to deliver CD28-mediated co-stimulation within the tumor.
  • ARM Platform Adaptive Immune Response Modulator platform for developing redesigned bispecific T-cell engagers to improve efficacy and durability of response with a large safety window, intended for autoimmune disease applications. First clinical candidate JANX011 targets CD19 for deep and durable B-cell depletion in autoimmune diseases.

Quantifiable outcome

  • Median radiographic progression-free survival of 7.9 to 8.9 months in mCRPC patients treated with JANX007 (Phase 1 data, December 2025)
  • +3 more outcomes

Companies that use Janux Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Janux Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Janux Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Bristol Myers Squibb (BMS)coreStrategic or Co-development Partner · 22 January 2026In January 2026, Janux entered a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across multiple cancer types. Janux receives $50M in upfront and near-term payments plus up to approximately $800M in additional milestones, plus tiered royalties on global sales. Janux conducts preclinical development through IND submission; BMS leads subsequent clinical development and global commercialization, with Janux remaining actively involved through completion of the first Phase 1 clinical study. A $35M milestone was triggered in April 2026 following nomination of a development candidate.
  • Merck & Co. (Merck Sharp & Dohme)coreStrategic or Co-development Partner · 1 December 2020In December 2020, Janux entered a research collaboration and exclusive license agreement with Merck to develop TRACTr two product candidates distinct from Janux's internally developed pipeline. Merck exercised its right to select both collaboration targets related to next-generation TCE immunotherapies for cancer treatment. In August 2025, Janux announced the first patient was dosed in the lead collaboration program. Deal value exceeds $1 billion in total potential payments.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Janux Therapeutics competitors and assessment

Company assessment

Direct peers

  • Compass Therapeutics: Clinical-stage biotech with bispecific antibody candidates (e.g., CD3-engaging formats) for oncology. Small capitalization peer with a comparable technology platform and indication focus.
  • MacroGenics: Develops DART and TRIDENT bispecific antibody platforms, including T cell engagers and ADCs targeting oncology antigens; partnered with multiple Big Pharma. Closely comparable format and indication overlap (solid tumors, hematologic cancers).
  • Xencor: Clinical-stage biotech with the XmAb bispecific antibody platform used by multiple partners to build T cell engagers (e.g., CD3-engaging formats) for oncology and autoimmune. Operates a similar platform-plus-partnership business model.
  • Zymeworks: Develops Azymetric bispecific antibodies and other multispecific platforms for oncology and autoimmune indications, including T cell engaging constructs; similar pipeline breadth and partnership-driven commercialization model.
  • Maverick Therapeutics: Pre-IPO developer of conditional T cell engagers (COBRA platform) targeting solid tumors, including a PSMA-directed candidate; acquired by Takeda in 2022. Closest technology competitor in masking-based TCEs.
  • Harpoon Therapeutics: Developed T cell engagers with a proprietary masking/half-life-extension platform (TriTAC) targeting solid tumor antigens including PSMA; acquired by Merck in 2024. Closest technology analog to Janux's TRACTr platform and now a program counterpart inside Janux's Merck partner.
  • Genmab: Owns the DuoBody bispecific platform used in oncology therapeutics including T cell engagers and antibody-drug conjugates; partnered broadly with Big Pharma. Direct structural analog to Janux's bispecific platform strategy.

Broad incumbents

  • Amgen: Pioneered the BiTE platform (blinatumomab is approved) and continues to develop CD3-bispecifics across solid and hematologic tumors; sets the competitive baseline for any new TCE entrant in oncology.
  • Regeneron Pharmaceuticals: Develops CD3-engaging bispecific antibodies (e.g., CD20×CD3 linvoseltamab, earlier REGN1979) as part of a large oncology and immunology portfolio. Operates bispecific programs at greater scale and commercial reach than Janux.

Emerging players

  • Cullinan Therapeutics: Clinical-stage developer of precision oncology biologics including T cell engaging modalities; smaller-cap competitor with overlapping bispecific/TCE approaches for solid tumors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Janux Therapeutics social profiles

Digital presence

Janux Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Janux Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Janux Therapeutics funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Janux Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Janux Therapeutics

What does Janux Therapeutics do?

Janux Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies using three proprietary platforms (TRACTr, TRACIr, and ARM) that employ peptide masking technology to keep T cell-binding domains inactive until cleaved by tumor-specific proteases in the tumor microenvironment. Its pipeline includes PSMA-directed T cell engagers for metastatic castration-resistant prostate cancer (JANX007, JANX014), a CD19-targeted candidate for autoimmune disease (JANX011), and a PSMA-directed T cell costimulator (JANX013), with commercialization rights primarily licensed to Merck and Bristol Myers Squibb.

Is Janux Therapeutics a public or private company?

Janux Therapeutics is a public company. It is classified as public and is currently operating.

When was Janux Therapeutics founded?

Janux Therapeutics was founded in 2017. It employs 101 to 250 people.

Where is Janux Therapeutics based?

Janux Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Janux Therapeutics make money?

Three revenue lines are on record. Strategic Partnerships and Licensing (Merck) is the primary driver. The others are strategic Partnerships and Licensing (Bristol Myers Squibb) and milestone Payments from Partnerships.

Who are Janux Therapeutics's main competitors?

Direct peers on record are Compass Therapeutics, MacroGenics, Xencor, Zymeworks, Maverick Therapeutics, Harpoon Therapeutics and Genmab. Broad incumbents are Amgen and Regeneron Pharmaceuticals. Cullinan Therapeutics is listed as an emerging player.

Does Janux Therapeutics have an API?

No public API is recorded for Janux Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaJanux Therapeutics: Potential JANX007 Comeback mCRPC And Initial JANX011 DataJanux Therapeutics' JANX007 phase 1b data for taxane-naive mCRPC are expected in the first half of 2027, with a shift toward earlier-line, lower-burden patients. JANX011 showed B-cell depletion in healthy volunteers, with ITP and RA proof-of-concept studies planned for 2027. The company holds $945.7 million in cash and investments.American Banking and Market NewsJanux Therapeutics (NASDAQ:JANX) Stock Dropped to Peer Perform by Wolfe ResearchWolfe Research downgraded Janux Therapeutics from outperform to peer perform. Analysts have a consensus Moderate Buy rating with an average target price of $36.92. The stock opened at $11.49, down 7.3%.TradingViewWolfe Research downgrades Janux Therapeutics to Peer Perform from OutperformWolfe Research downgraded Janux Therapeutics to Peer Perform from Outperform. Recent analyst price targets for the stock range from $15 to $40, with Truist, Wedbush, and Barclays maintaining their ratings.Investing.comWhy is Janux Therapeutics stock sliding today?Janux Therapeutics stock fell 3.5% in pre-open trading, trading at $11.96 near its 52-week low of $11.59. The decline follows last week's Phase 1 data for JANX011, which triggered a 25% plunge. Analysts hold Buy ratings, but the stock has dropped over 54% in twelve months.Investing.comH.C. Wainwright reiterates Janux Therapeutics stock rating at buyH.C. Wainwright reiterated a Buy rating and $45 price target on Janux Therapeutics, which trades at $12.39. The firm cited Phase 1 data showing deep B-cell depletion at 3 mg, with no serious adverse events. Analysts expect earnings on November 6.Investing.comJanux reports phase 1 data for autoimmune drug candidate JANX011Janux Therapeutics reported Phase 1 data for JANX011, a CD19-targeted bispecific T-cell engager, in 25 healthy volunteers. At the 3 mg dose, three of five participants achieved over 90% B-cell depletion, with reductions persisting through Day 42. The company plans to advance JANX011 into patient studies for immune thrombocytopenia and rheumatoid arthritis in 2027.Simply Wall StJanux Therapeutics (JANX) Earnings Beat Puts Its Pricey Valuation Back In FocusJanux Therapeutics reported Q3 results with a narrower net loss and revenue above expectations, lifting its stock nearly 10%. The company trades at a 46.3x price-to-sales ratio, far above the industry average of 9.7x, implying a potentially overvalued market price.American Banking and Market NewsTruist Financial Forecasts Strong Price Appreciation for Janux Therapeutics (NASDAQ:JANX) StockTruist Financial raised its price target on Janux Therapeutics to $27 from $26, maintaining a buy rating. The company reported a Q3 loss of $0.34 per share, beating the expected $0.45–$0.47, with revenue of $9.29 million exceeding the $8.03 million estimate. Analysts have a consensus target of $36.92.TradingViewTruist Securities maintains Janux Therapeutics at Buy, raises price target to $27 from $26Truist Securities maintained Janux Therapeutics at Buy and raised its price target to $27 from $26, a 3.8% increase. The target implies a 68.1% upside from the Nov 5 close of $16.06.TradingViewWedbush maintains Janux Therapeutics at Outperform, raises price target to $40 from $36Wedbush maintained Janux Therapeutics at Outperform and raised its price target to $40 from $36, an 11.1% increase. The target implies an upside of 149.1% from the Nov 5 close of $16.06.